Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments

Table 1 Characteristics of the study patients

	Number of patients
*Age at F1CDx (years)**	62.9 (33.4–82.1)
Past medical history
Metachronal breast cancer	0
Ovarian cancer	0
Adult T-cell leukemia	1
Family medical history
Breast cancer	3
Ovarian cancer	0
Other cancers^†	3
TNM stage at initial diagnosis^‡
I	2
II	10
III	6
IV	3
Unknown	1
Surgical procedure
Mastectomy	15
Partial resection	4
None^§	3
Lines of previous chemotherapy^\|\|
0	9
1	2
2	11
Tissue source
Biopsy specimen^¶	16
Surgery specimen	6

* Median (range)
^†Other cancers included lung cancer (n = 1), cervical cancer (n = 1), and endometrial cancer (n = 1)
^‡ UICCs, 8th edition
^§ Patients with clinical stage IV disease at diagnosis
^||Previous chemotherapy includes the number of chemotherapeutic treatments that had affected the tumor biology before taking the samples that were served for F1CDx and F1CDx-Liquid
^¶Biopsy specimen include skin (n = 4), lymph node (n = 3), lung (n = 2), liver (n = 1), remnant breast (n = 1) and primary breast tumor (n = 2)

ISSN: 1471-2407